Opportunity Information: Apply for RFA AI 12 014
Apply for RFA AI 12 014
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Partnerships for Development of Vaccine Technologies (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Feb 1, 2012 and posted on Feb 1, 2012.
- Applicants must submit their applications by Jun 26, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $9,300,000.00 to eligible and selected applicants.
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities County governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments City or township governments Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Partnerships for Development of Vaccine Technologies (R01) is a National Institute of Allergy and Infectious Diseases (NIAID), NIH funding opportunity (RFA-AI-12-014) aimed at pushing promising vaccine-enabling technologies through preclinical development so they are closer to real-world use during a naturally occurring infectious disease outbreak or a deliberate release of a harmful pathogen. The emphasis is not on basic discovery, but on practical, readiness-focused work that could measurably improve how well vaccines work and/or make vaccination easier to deliver to the people who need it, when speed and scale matter most. The FOA explicitly includes technologies such as adjuvants, reflecting an interest in approaches that can strengthen immune responses, improve dose-sparing, broaden protection, or enhance durability, as well as tools that simplify administration and deployment in emergency settings.
A defining feature of this announcement is its partnership model. Applicants are expected to show meaningful industry participation, with at least one industrial partner making a substantive investment in the project. This requirement signals that NIAID wanted proposals with a clear path toward development, manufacturing feasibility, and eventual adoption, rather than purely academic proofs of concept. In practical terms, this often means the project should be structured around a translational plan that an industry collaborator is willing to support with resources, expertise, materials, or other tangible commitments that increase the likelihood the technology can progress beyond the lab.
Applications were required to include a Product Development Strategy attachment, which reinforces the program’s development-oriented nature. This attachment would typically lay out how the technology will be matured and assessed in preclinical settings, including development milestones, key experiments, go/no-go criteria, and considerations tied to productization such as formulation, stability, scalability, and how the technology would integrate with vaccine platforms or delivery workflows. The overall intent is to make sure proposed studies are organized like a development program, not just a collection of experiments, and that applicants have thought through the steps needed to de-risk the technology for later stages.
The funding mechanism is an NIH R01 research project grant under the discretionary grant category, aligned with CFDA programs 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The announcement reported an estimated total funding level of $9.3 million. There was no cost sharing or matching requirement. Key dates were posted and created on February 1, 2012, with an original and current application closing date of June 26, 2012, and an archive date of July 27, 2012.
Eligibility was broad and included many types of organizations that might contribute to vaccine technology development. Eligible applicants included for-profit organizations (including small businesses), nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, and a wide range of government entities (state, county, city/township, special district governments), along with public housing authorities/Indian housing authorities. The FOA also noted eligibility for groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Importantly, non-U.S. entities (foreign institutions) were eligible to apply, and foreign components of U.S. organizations were allowed, consistent with NIH policy.
Overall, this FOA was designed to accelerate preclinical, partner-backed vaccine technology development that could translate into better performance and easier deployment of vaccines under urgent public health scenarios. The central expectations were a clear, development-grade plan (captured in the Product Development Strategy) and credible industrial engagement strong enough to show the technology has a realistic route toward practical use.
Frequently Asked Questions (FAQs)
What is the Partnerships for Development of Vaccine Technologies (R01) opportunity?
It is a National Institute of Allergy and Infectious Diseases (NIAID), NIH funding opportunity (RFA-AI-12-014) that supports work to push promising vaccine-enabling technologies through preclinical development so they are closer to practical, real-world use during a naturally occurring infectious disease outbreak or a deliberate release of a harmful pathogen.
What is the main goal of this FOA?
The main goal is readiness-focused development: advancing vaccine technologies in a way that measurably improves vaccine performance and/or makes vaccination easier to deliver when speed and scale are critical. The emphasis is on development and practical translation rather than basic discovery.
Is this opportunity focused on basic vaccine discovery research?
No. The FOA emphasizes practical, development-oriented work designed to mature vaccine-enabling technologies through preclinical development, rather than basic discovery or early exploratory concepts without a clear development path.
What kinds of technologies does the FOA cover?
The FOA includes vaccine-enabling technologies such as adjuvants and other approaches intended to strengthen immune responses, enable dose-sparing, broaden protection, enhance durability of protection, and simplify administration and deployment in emergency settings.
Why does the FOA mention adjuvants specifically?
Adjuvants are explicitly included because they can improve vaccine immune responses and may support goals like dose-sparing, broader protection, or more durable immunity, which are important when rapid, large-scale vaccination is needed.
What does "preclinical development" mean in the context of this announcement?
In this FOA, preclinical development refers to maturing and assessing the technology before human studies, with an emphasis on readiness and de-risking steps that make the technology more feasible for later-stage development and real-world deployment.
What makes this FOA a "partnership" opportunity?
A defining feature is the partnership model: applicants are expected to show meaningful industry participation, including at least one industrial partner making a substantive investment in the project. This is meant to strengthen the path toward development, manufacturing feasibility, and eventual adoption.
Is an industry partner required?
Based on the FOA description provided, applicants were expected to include meaningful industry participation, with at least one industrial partner making a substantive investment in the project.
What counts as "substantive investment" from an industrial partner?
The FOA description indicates the industrial partner should make a tangible commitment that increases the likelihood the technology can progress beyond the lab. Examples mentioned include resources, expertise, materials, or other concrete support, reflecting real development and manufacturing considerations.
Why does NIAID emphasize industry participation?
The emphasis signals a preference for proposals with a credible route toward development, manufacturing feasibility, and eventual adoption, rather than purely academic proof-of-concept studies.
What is the Product Development Strategy attachment?
Applications were required to include a Product Development Strategy attachment. This reinforces that the program is development-oriented and expects applicants to present a structured plan for maturing the technology through preclinical stages.
What should a Product Development Strategy cover (at a high level)?
Based on the description provided, it would typically outline development milestones, key preclinical experiments, go/no-go criteria, and productization considerations such as formulation, stability, scalability, and how the technology would integrate with vaccine platforms or delivery workflows.
How is this FOA different from proposing a set of experiments?
The FOA intent is that proposed studies are organized like a development program, not just a collection of experiments. Applicants were expected to show a milestone-driven plan with decision criteria and practical considerations that de-risk the technology for later stages.
What funding mechanism is used?
The funding mechanism is an NIH R01 research project grant under the discretionary grant category.
What CFDA programs are associated with this opportunity?
The FOA is aligned with CFDA 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
How much funding was estimated to be available?
The announcement reported an estimated total funding level of $9.3 million.
Is cost sharing or matching required?
No. The FOA states there was no cost sharing or matching requirement.
What were the key posted dates for this opportunity?
The FOA was created and posted on February 1, 2012. The original and current application closing date was June 26, 2012. The archive date was July 27, 2012.
Is this FOA still open for applications?
No. Based on the dates provided, the application closing date was June 26, 2012, and the opportunity was archived on July 27, 2012.
Who was eligible to apply?
Eligibility was broad and included for-profit organizations (including small businesses), nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, and many government entities (state, county, city/township, special district governments), plus public housing authorities/Indian housing authorities.
Are minority-serving institutions and community-based organizations eligible?
Yes. The FOA noted eligibility for organizations including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, and regional organizations.
Are U.S. territories or possessions eligible to apply?
Yes. The FOA noted eligibility for U.S. territories or possessions.
Can federal agencies apply?
Yes. The FOA indicated that eligible federal agencies could apply.
Are non-U.S. (foreign) institutions eligible?
Yes. The FOA stated that non-U.S. entities (foreign institutions) were eligible to apply, consistent with NIH policy.
Are foreign components of U.S. organizations allowed?
Yes. The FOA noted that foreign components of U.S. organizations were allowed, consistent with NIH policy.
What public health scenarios is this FOA designed to support?
It is designed to help prepare vaccine technologies for urgent scenarios, including naturally occurring infectious disease outbreaks and deliberate releases of harmful pathogens, where rapid and scalable vaccination can be critical.
What does the FOA mean by "readiness-focused" outcomes?
The FOA emphasizes work that moves technologies closer to practical use by addressing development questions and constraints (for example, stability, scalability, integration with vaccine platforms, and emergency deployment considerations), so the technology is better positioned for real-world adoption.
What are examples of improvements the FOA aims to enable?
Examples described include strengthening immune responses, improving dose-sparing, broadening protection, enhancing durability, and simplifying vaccine administration and deployment in emergency settings.
Browse more opportunities from the same category: Health
Next opportunity: Education/Interpretation Intern for Manassas National Battlefield Park
Previous opportunity: The Corps Networks 2012 Annual Forum
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 12 014
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 12 014) also looked into and applied for these:
| Funding Opportunity |
|---|
| Resource Access for the Bridging Interventional Development Gaps Program (X01) Apply for PAR 12 092 Funding Number: PAR 12 092 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NU HITES Apply for RFA 617 12 000005 Funding Number: RFA 617 12 000005 Agency: Uganda USAID Kampala Category: Health Funding Amount: $50,000,000 |
| Strengthening Systems, Capacity, and Data Collection with a Focus on Strategic Information in South Sudan under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1256 Funding Number: CDC RFA GH12 1256 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Engaging Local Indigenous Organizations in Improving Quality and Efficiency of HIV Care and Treatment Services in Ukraine under the Presidents Emergency Plan for HIV/AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1227 Funding Number: CDC RFA GH12 1227 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $700,000 |
| Establishment of an expanded Caribbean HIV/AIDS monitoring and evaluation technical assistance unit within the Caribbean Health Research Council (CHRC) under the Presidents Emergency Plan for AIDS Relief (PEPFAR Apply for CDC RFA GH12 1205 Funding Number: CDC RFA GH12 1205 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Planning Grant The Money Follows the Person Rebalancing Demonstration Program Apply for CMS 1LI 12 001 Funding Number: CMS 1LI 12 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $200,000 |
| Expanding Participation of People with Disabilities in USAID Activities andStrengthen the Capacities of Disabled Peoples Organizations (DPOs) Apply for RFA 114 12 000002 Funding Number: RFA 114 12 000002 Agency: Georgia USAID Tbilisi Category: Health Funding Amount: $600,000 |
| Implementation of a Program to Build the Institutional Apply for CDC RFA GH12 1243 Funding Number: CDC RFA GH12 1243 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,130,000 |
| Modeling Social Behavior (R01) Apply for RFA GM 13 006 Funding Number: RFA GM 13 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grand Challenges in Global Mental Health Integrating Mental Health into Chronic Disease Care Provision in Low and Middle Income Countries (R01) Apply for RFA MH 13 040 Funding Number: RFA MH 13 040 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Increasing Human Resources for Health and Epidemiological Capacity in the Republic of Guyana through a University Training Program under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1208 Funding Number: CDC RFA GH12 1208 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $440,000 |
| Sober Truth on Preventing Underage Drinking Act Grants Apply for SP 12 003 Funding Number: SP 12 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $50,000 |
| Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1250 Funding Number: CDC RFA GH12 1250 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $8,000,000 |
| Ancillary Studies in PREDICT HD (U01) Apply for PAR 12 097 Funding Number: PAR 12 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ancillary Domain Validation Patient Reported Outcomes Measurement Information System (PROMIS) Studies (R01) Apply for RFA AR 12 007 Funding Number: RFA AR 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| National Forum for State and Territorial Chief Executives Apply for HRSA 12 152 Funding Number: HRSA 12 152 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Reduce the Incidence and Mitigate the Impact of HIV/AIDS in Mali under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1231 Funding Number: CDC RFA GH12 1231 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Technical Assistance to The Ministry of Health (MOH) for HIV Services and Program Transition in Zambezia Province of the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1224 Funding Number: CDC RFA GH12 1224 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $25,000,000 |
| Stem Cell Approaches to Developing New Therapies for Ocular Diseases (R01) Apply for RFA EY 12 001 Funding Number: RFA EY 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Strong Start for Mothers and Newborns Apply for CMS 1D1 12 001 Funding Number: CMS 1D1 12 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 12 014", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.